Галерея 3449660
🛑 ПОДРОБНЕЕ ЖМИТЕ ЗДЕСЬ 👈🏻👈🏻👈🏻
Галерея 3449660
false 0001556593 0001556593 2020-06-18 2020-06-18 0001556593 us-gaap:SeriesCPreferredStockMember 2020-06-18 2020-06-18 0001556593 us-gaap:SeriesBPreferredStockMember 2020-06-18 2020-06-18 0001556593 us-gaap:SeriesAPreferredStockMember 2020-06-18 2020-06-18 0001556593 us-gaap:CommonStockMember 2020-06-18 2020-06-18
PURSUANT TO SECTION 13 OR 15(d) OF THE
Date of Report (Date of earliest event reported): June 18, 2020
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation)
1345 Avenue of the Americas , 45th Floor
(Address of principal executive offices)
Registrant’s telephone number, including area code ( 212 ) 479-3150
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Name of each exchange on which registered:
Common Stock, $0.01 par value per share
7.50% Series A Fixed-to-Floating Rate Cumulative Redeemable Preferred Stock
7.125% Series B Fixed-to-Floating Rate Cumulative Redeemable Preferred Stock
6.375% Series C Fixed-to-Floating Rate Cumulative Redeemable Preferred Stock
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934
(§240.12b-2 of this chapter).
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the
Exchange Act. ☐
Submission of Matters to a Vote of Security Holders .
At the 2020 Annual Meeting of Stockholders (the “Annual Meeting”), held June 18, 2020, the stockholders of New Residential
Investment Corp. (the “Company”) voted on the matters described below.
The Company’s stockholders elected three Class I directors, who comprise all the directors of such class, to serve until the 2023 Annual Meeting of Stockholders and until their successors are elected and duly qualified. The numbers of
shares that voted for the election of such director, abstained from voting for such director, and represented broker non-votes with respect to this proposal are summarized in the table below.
The Company’s stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2020. The numbers of shares that voted for, against and
abstained from voting for or against the ratification of the selection of Ernst & Young LLP are summarized in the table below.
The Company’s stockholders did not approve an amendment to the Company’s bylaws to implement a majority voting standard for uncontested elections of directors. The numbers
of shares that voted for, against and abstained from voting for or against the proposal, and represented broker non-votes with respect to this proposal are summarized in the table below.
* Broker non-votes are instances where a broker holding shares of record for a beneficial owner does not vote the shares because it has not received voting instructions
from the beneficial owner and therefore is precluded by the rules of the New York Stock Exchange (“NYSE”) from voting on a particular matter. Under NYSE rules, when a broker holding shares in “street name” does not receive voting instructions
from a beneficial owner, the broker has discretionary authority to vote on certain routine matters but is prohibited from voting on non-routine matters. Brokers who did not receive instructions were not entitled to vote on the election of
directors or the amendment to the bylaws, but they were entitled to vote on the ratification of the appointment of the independent registered public accounting firm.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Chief Financial Officer and Chief Accounting Officer
Clipboard, Search History, and several other advanced features are temporarily unavailable.
Dashboard
Publications
Account settings
Log out
Advanced
Clipboard
Format
Abstract
PubMed
PMID
Format:
Summary (text)
PubMed
PMID
Abstract (text)
CSV
Subject:
1 selected item: 35222642 - PubMed
Format:
Summary
Summary (text)
Abstract
Abstract (text)
Create a new collection
Add to an existing collection
Name must be less than 100 characters
Unable to load your collection due to an error
Please try again
Unable to load your delegates due to an error
Please try again
Would you like email updates of new search results?
Saved Search Alert Radio Buttons
Yes
No
Frequency:
Monthly
Weekly
Daily
Which day?
The first Sunday
The first Monday
The first Tuesday
The first Wednesday
The first Thursday
The first Friday
The first Saturday
The first day
The first weekday
Which day?
Sunday
Monday
Tuesday
Wednesday
Thursday
Friday
Saturday
Report format:
Summary
Summary (text)
Abstract
Abstract (text)
PubMed
Send at most:
1 item
5 items
10 items
20 items
50 items
100 items
200 items
Send even when there aren't any new results
Number of items displayed:
5
10
15
20
50
100
Create a new collection Add to an existing collection
Name must be less than 100 characters
Unable to load your collection due to an error Please try again
Page navigation
Title & authors
Abstract
Conflict of interest statement
Figures
Similar articles
Cited by
References
Related information
LinkOut - more resources
Affiliations
1 Oncology Department, Hôpital Européen Georges Pompidou, AP-HP, Université de Paris, Paris 75015, France.
2 Medical Oncology Unit, Institut de Cancérologie Strasbourg Europe, Strasbourg 67200, France.
3 Oncology Department, Institut Gustave Roussy, Université Paris-Saclay, Villejuif 94076, France.
4 Department of Medical Oncology, Centre Oscar Lambret, Lille 59000, France.
5 Department of Medical Oncology, Centre Antoine-Lacassagne, Université Côte d'Azur, Nice 06100, France.
6 Medical Oncology Department, Hôpital Cochin-Port Royal, AP-HP, Paris75014, France.
7 Department of Medical Oncology, Institut Mutualiste Montsouris, Paris 75014, France.
8 Department of Oncology, Hôpital Pitié Salpêtrière, AP-HP, Paris 75013, France.
9 Department of Medical Oncology, Centre Hospitalier Universitaire de Besançon, Besançon 25000, France.
10 Medical Oncology Department, Centre François Baclesse, Caen 14000, France.
11 Oncology Department, Centre Eugène Marquis, Rennes 35000, France.
12 Oncology Department, Clinique Sainte-Marguerite, Hyères 83400, France.
13 Department of Medical Oncology, Institut Universitaire du Cancer Toulouse-Oncopole, Toulouse 31100, France.
14 Oncology and Supportive Care Department, Hôpital Foch, Suresnes 92150, France.
15 Department of Medical Oncology, Centre Léon Bérard, Lyon 69008, France.
16 Department of Medical Oncology, Centre Hospitalier Universitaire de Bordeaux-Hôpital Saint-André, Bordeaux 33000, France.
17 Centre de Recherche des Cordeliers, INSERM, Université de Paris, Sorbonne Université, Paris 75006, France.
18 Université de Paris, PARCC, INSERM U970, Paris 75006, France.
Charles Vauchier et al.
J Oncol .
2022 .
Format
Abstract
PubMed
PMID
Affiliations
1 Oncology Department, Hôpital Européen Georges Pompidou, AP-HP, Université de Paris, Paris 75015, France.
2 Medical Oncology Unit, Institut de Cancérologie Strasbourg Europe, Strasbourg 67200, France.
3 Oncology Department, Institut Gustave Roussy, Université Paris-Saclay, Villejuif 94076, France.
4 Department of Medical Oncology, Centre Oscar Lambret, Lille 59000, France.
5 Department of Medical Oncology, Centre Antoine-Lacassagne, Université Côte d'Azur, Nice 06100, France.
6 Medical Oncology Department, Hôpital Cochin-Port Royal, AP-HP, Paris75014, France.
7 Department of Medical Oncology, Institut Mutualiste Montsouris, Paris 75014, France.
8 Department of Oncology, Hôpital Pitié Salpêtrière, AP-HP, Paris 75013, France.
9 Department of Medical Oncology, Centre Hospitalier Universitaire de Besançon, Besançon 25000, France.
10 Medical Oncology Department, Centre François Baclesse, Caen 14000, France.
11 Oncology Department, Centre Eugène Marquis, Rennes 35000, France.
12 Oncology Department, Clinique Sainte-Marguerite, Hyères 83400, France.
13 Department of Medical Oncology, Institut Universitaire du Cancer Toulouse-Oncopole, Toulouse 31100, France.
14 Oncology and Supportive Care Department, Hôpital Foch, Suresnes 92150, France.
15 Department of Medical Oncology, Centre Léon Bérard, Lyon 69008, France.
16 Department of Medical Oncology, Centre Hospitalier Universitaire de Bordeaux-Hôpital Saint-André, Bordeaux 33000, France.
17 Centre de Recherche des Cordeliers, INSERM, Université de Paris, Sorbonne Université, Paris 75006, France.
18 Université de Paris, PARCC, INSERM U970, Paris 75006, France.
Response to ICI-2 stratified by (a) best response to ICI-1 ( p =0.31), (b) reason for ICI-1 discontinuation ( p =0.18), and (c) therapy received at ICI-2 ( p =0.57).CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease.
ICI-2 progression-free survival according to ICI-1 PFS. PFS, progression-free survival; CI, confidence interval; NR, not reached; mo, months.
Factors associated with PFS at ICI-2 (multivariate analysis). HR, hazard ratio; CI, confidence interval; IMDC, International Metastatic Renal Cell Carcinoma Database Consortium; ICI, immune checkpoint inhibitors; PFS, progression-free surviva l. Note . ∗ Among significant factors in univariate analysis, the three most relevant variables were selected for multivariate analysis. The others were not included due to a lack of power.
Quhal F, Mori K, Bruchbacher A, Resch I, Mostafaei H, Pradere B, Schuettfort VM, Laukhtina E, Egawa S, Fajkovic H, Remzi M, Shariat SF, Schmidinger M.
Quhal F, et al.
Eur Urol Oncol. 2021 Oct;4(5):755-765. doi: 10.1016/j.euo.2021.03.001. Epub 2021 Mar 20.
Eur Urol Oncol. 2021.
PMID: 33757737
Review.
Carril-Ajuria L, Colomba E, Romero-Ferreiro C, Cerbone L, Ratta R, Barthelemy P, Vindry C, Fléchon A, Cherifi F, Boughalem E, Linassier C, Fornarini G, Rebuzzi SE, Gross-Goupil M, Saldana C, Martin-Soberón M, de Velasco G, Manneh R, Pernaut C, Sanchez de Torre A, Flippot R, Escudier B, Albiges L.
Carril-Ajuria L, et al.
Eur J Cancer. 2023 Feb;180:21-29. doi: 10.1016/j.ejca.2022.11.013. Epub 2022 Nov 26.
Eur J Cancer. 2023.
PMID: 36527973
Martini DJ, Olsen TA, Goyal S, Liu Y, Evans ST, Hitron EE, Russler GA, Yantorni L, Caulfield S, Brown JT, Goldman JM, Nazha B, Carthon BC, Harris WB, Kucuk O, Master VA, Bilen MA.
Martini DJ, et al.
J Immunother Precis Oncol. 2022 Jun 14;5(3):52-57. doi: 10.36401/JIPO-22-2. eCollection 2022 Aug.
J Immunother Precis Oncol. 2022.
PMID: 36034580
Free PMC article.
Ma VT, Su CT, Hu M, Taylor JMG, Daignault-Newton S, Kellezi O, Dahl MN, Shah MA, Erickson S, Lora J, Hamasha R, Ali A, Yancey S, Kiros L, Balicki HM, Winfield DC, Green MD, Alva AS.
Ma VT, et al.
Urol Oncol. 2021 Jul;39(7):437.e1-437.e9. doi: 10.1016/j.urolonc.2021.01.006. Epub 2021 Jan 23.
Urol Oncol. 2021.
PMID: 33495117
Free PMC article.
Auvray M, Auclin E, Barthelemy P, Bono P, Kellokumpu-Lehtinen P, Gross-Goupil M, De Velasco G, Powles T, Mouillet G, Vano YA, Gravis G, Mourey L, Priou F, Rolland F, Escudier B, Albiges L.
Auvray M, et al.
Eur J Cancer. 2019 Feb;108:33-40. doi: 10.1016/j.ejca.2018.11.031. Epub 2019 Jan 5.
Eur J Cancer. 2019.
PMID: 30616146
Larroquette M, Lefort F, Heraudet L, Bernhard JC, Ravaud A, Domblides C, Gross-Goupil M.
Larroquette M, et al.
Cancers (Basel). 2022 Dec 17;14(24):6230. doi: 10.3390/cancers14246230.
Cancers (Basel). 2022.
PMID: 36551715
Free PMC article.
Review.
Papathanassiou M, Tamposis I, Exarchou-Kouveli KK, Kontou PI, de Paz AT, Mitrakas L, Samara M, Bagos PG, Tzortzis V, Vlachostergios PJ.
Papathanassiou M, et al.
Front Oncol. 2022 Dec 2;12:996553. doi: 10.3389/fonc.2022.996553. eCollection 2022.
Front Oncol. 2022.
PMID: 36531034
Free PMC article.
Mitsogiannis IC, Mitsogianni M, Papathanassiou M, Anagnostou M, Tamposis I, Mitrakas L, Samara M, Tzortzis V, Vlachostergios PJ.
Mitsogiannis IC, et al.
J Kidney Cancer VHL. 2022 Sep 29;9(3):29-40. doi: 10.15586/jkcvhl.v9i3.243. eCollection 2022.
J Kidney Cancer VHL. 2022.
PMID: 36310639
Free PMC article.
Review.
Related information
MedGen
Format:
AMA
APA
MLA
NLM
Send To
Clipboard
Email
Save
My Bibliography
Collections
Citation Manager
[x]
NLM
NIH
HHS
USA.gov
An official website of the United States government
The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before
sharing sensitive information, make sure you’re on a federal
government site.
The site is secure.
The https:// ensures that you are connecting to the
official website and that any information you provide is encrypted
and transmitted securely.
Introduction:
Immune checkpoint inhibitors (ICI) have been approved for front-line therapy in metastatic renal cell carcinoma (mRCC). However, progressive disease often occurs and subsequent therapies are needed. ICI rechallenge may be an option, but there is a lack of data regarding efficacy and prognostic factors. We assessed efficacy of ICI rechallenge and factors associated with better outcomes. Patients and Methods . This ambispective multicenter study included 45 mRCC patients rechallenged with nivolumab ± ipilimumab between 2014 and 2020. Primary end
Галерея 2964548
Опытная дамочка принимает участие в сумасшедших оргиях и ей это очень нравится
Веселая компания хорошо проводит время исследуя тела друг друга и забывая обо всяких приличиях